pharmaphorum

JANUARY 6, 2021

million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. The nomination of a first candidate in the collaboration that will advance into development triggers a $2.5

Gene Silencing 60

Gene Silencing Gene RNA Contract Manufacturing 60

pharmaphorum

OCTOBER 27, 2020

The company opted to test merimepodib in the combination trial first as that had the greatest potential to make a difference to patients, but the safety issue means that it has decided to halt development of the drug altogether. Just a few weeks later, and the study comparing Veklury plus merimepodib to Veklury plus placebo has failed.

Drug Trials 98

Drug Trials Trials Drugs Contract Manufacturing 98

pharmaphorum

JANUARY 7, 2021

It gave CureVac €75 million in funding to develop CVnCoV last July, adding to around €100 million provided by the German government in 2020. At last count, there are more than 60 coronavirus vaccines at in clinical development around the world, with another 170 in preclinical testing, according to the World Health Organization (WHO).

Vaccination 104

Vaccination Vaccine Contract Manufacturing Development 104

The Pharma Data

NOVEMBER 17, 2021

Pfizer has begun and will continue to invest up to roughly$ 1 billion of its own finances to support the manufacturing and distribution of this investigational treatment seeker. PF-07321332 inhibits viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

HR 52

HR Manufacturing Contract Manufacturing Licensing 52

The Pharma Data

NOVEMBER 19, 2021

.” PF-07321332 is designed to block the exertion of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate, at a stage known as proteolysis-which occurs before viral RNA replication. Each case was randomized (11) to admit PAXLOVID or placebo orally every 12 hours for five days.

HR 52

HR Contract Manufacturing Manufacturing Clinical Trials 52

The Pharma Data

MARCH 22, 2022

Pfizer continues to invest to support the manufacturing and distribution of PAXLOVID, including exploring potential contract manufacturing options. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

In-Vitro 52

In-Vitro Contract Manufacturing Manufacturing Production 52

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . Thompson says that the development of Covid-19 vaccines, which used mRNA technology, resulted in wider acceptance for cell and gene therapies. . “On

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52